Scilex Holding Company provided sales guidance for the fiscal year ended December 31, 2023. For the period, the company expects total product net sales were in the range of $46.5 million to $52.5 million, compared to $38.0 million for the fiscal year ended December 31, 2022, representing growth in the range of approximately 22% to 38%.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.09 USD | -1.80% | -3.54% | -46.57% |
May. 30 | Sector Update: Health Care Stocks Mixed Late Afternoon | MT |
May. 30 | Sector Update: Health Care | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-46.57% | 132M | |
+15.54% | 78.51B | |
+12.05% | 9B | |
+58.17% | 4.96B | |
-14.94% | 4.84B | |
-.--% | 3.72B | |
+21.94% | 2.48B | |
-26.63% | 2.19B | |
+16.75% | 2.12B | |
-37.97% | 1.94B |
- Stock Market
- Equities
- SCLX Stock
- News Scilex Holding Company
- Scilex Holding Company Provides Sales Guidance for the Fiscal Year Ended December 31, 2023